- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 473/28 - Atome d'oxygène
Détention brevets de la classe C07D 473/28
Brevets de cette classe: 48
Historique des publications depuis 10 ans
|
3
|
1
|
5
|
8
|
2
|
3
|
1
|
2
|
0
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2704 |
6 |
| Novartis AG | 10904 |
2 |
| The Regents of the University of California | 19812 |
2 |
| Idemitsu Kosan Co., Ltd. | 4152 |
2 |
| Dainippon Sumitomo Pharma Co., Ltd. | 196 |
2 |
| Signal Pharmaceuticals, LLC | 180 |
2 |
| Changzhou Longthera Pharmaceuticals Inc | 2 |
2 |
| Impetis Biosciences Ltd. | 29 |
2 |
| AstraZeneca AB | 2928 |
1 |
| Janssen Pharmaceutica N.V. | 3423 |
1 |
| ALT Solutions Inc. | 1 |
1 |
| Betta Pharmaceuticals Co., Ltd. | 177 |
1 |
| Cancer Research Technology Limited | 521 |
1 |
| Clavis Pharma AS | 1 |
1 |
| Conforma Therapeutics Corporation | 6 |
1 |
| Dana-Farber Cancer Institute, Inc. | 2553 |
1 |
| Denali Therapeutics Inc. | 240 |
1 |
| Forma Therapeutics, Inc. | 159 |
1 |
| Inspyr Therapeutics, Inc. | 3 |
1 |
| The Institute of Cancer Research: Royal Cancer Hospital | 185 |
1 |
| Autres propriétaires | 16 |